April 5, 2010 (FinancialWire) — Hospira, Inc. (NYSE: HSP), a firm that provides generic injectable pharmaceuticals, said it has reached a legal settlement with French drugmaker Sanofi-Aventis (NYSE: SNY) to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin.

Under the settlement terms, Hospira will stop selling oxaliplatin injection in the United States by June 30, 2010, and can relaunch the product in the United States on August 9, 2012.

Hospira said the settlement will not affect its financial guidance for 2010.

Hospira launched oxaliplatin injection in August 2009 following a favorable ruling in the patent litigation with Sanofi-Aventis. That decision was later vacated by the appellate court.

By settling the litigation, Hospira said it will secure the right to relaunch its oxaliplatin products more than a year in advance of the expiration of the patent at issue.

Oxaliplatin injection, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor, and in the treatment of advanced colorectal cancer.

Illinois-based Hospira is a specialty pharmaceutical and medication delivery company.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.